243 related articles for article (PubMed ID: 34174984)
1. The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond.
Ding W
Hematol Oncol Clin North Am; 2021 Aug; 35(4):739-759. PubMed ID: 34174984
[TBL] [Abstract][Full Text] [Related]
2. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
3. Richter transformation of chronic lymphocytic leukemia in the era of novel agents.
Wang Y; Ding W
Clin Adv Hematol Oncol; 2020 Jun; 18(6):348-357. PubMed ID: 32649656
[TBL] [Abstract][Full Text] [Related]
4. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Bouclet F; Calleja A; Dilhuydy MS; Véronèse L; Pereira B; Amorim S; Cymbalista F; Herbaux C; de Guibert S; Roos-Weil D; Hivert B; Aurran T; Dupuis J; Blouet A; Tchernonog E; Laribi K; Dmytruck N; Morel P; Michallet AS; Dartigeas C; Tournilhac O; Nguyen-Khac F; Delmer A; Feugier P; Ysebaert L; Guièze R
Ann Hematol; 2021 Apr; 100(4):987-993. PubMed ID: 33495922
[TBL] [Abstract][Full Text] [Related]
5. SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation.
Burke JM
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):427-435. PubMed ID: 35577753
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
7. Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.
Molica S; Tam C; Allsup D; Polliack A
Hematol Oncol; 2024 Jan; 42(1):e3238. PubMed ID: 37937506
[TBL] [Abstract][Full Text] [Related]
8. Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy.
Jamroziak K; Tadmor T; Robak T; Polliack A
Leuk Lymphoma; 2015 Jul; 56(7):1949-58. PubMed ID: 25356923
[TBL] [Abstract][Full Text] [Related]
9. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
Liu W; Burger JA; Xu J; Tang Z; Toruner G; Khanlari M; Medeiros LJ; Tang G
Ann Hematol; 2020 Oct; 99(10):2343-2349. PubMed ID: 32833105
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.
Lew TE; Lin VS; Cliff ER; Blombery P; Thompson ER; Handunnetti SM; Westerman DA; Kuss BJ; Tam CS; Huang DCS; Seymour JF; Roberts AW; Anderson MA
Blood Adv; 2021 Oct; 5(20):4054-4058. PubMed ID: 34478505
[TBL] [Abstract][Full Text] [Related]
11. BTK Inhibitors in Chronic Lymphocytic Leukemia.
Gaballa S; Pinilla-Ibarz J
Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
[TBL] [Abstract][Full Text] [Related]
12. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
Gonzalez D; Martinez P; Wade R; Hockley S; Oscier D; Matutes E; Dearden CE; Richards SM; Catovsky D; Morgan GJ
J Clin Oncol; 2011 Jun; 29(16):2223-9. PubMed ID: 21483000
[TBL] [Abstract][Full Text] [Related]
13. Prognostication in chronic lymphocytic leukemia.
Moia R; Gaidano G
Semin Hematol; 2024 Apr; 61(2):83-90. PubMed ID: 38523019
[TBL] [Abstract][Full Text] [Related]
14. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
Tam CS; Stilgenbauer S
Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428
[TBL] [Abstract][Full Text] [Related]
15. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
Rossi D; Fangazio M; Rasi S; Vaisitti T; Monti S; Cresta S; Chiaretti S; Del Giudice I; Fabbri G; Bruscaggin A; Spina V; Deambrogi C; Marinelli M; Famà R; Greco M; Daniele G; Forconi F; Gattei V; Bertoni F; Deaglio S; Pasqualucci L; Guarini A; Dalla-Favera R; Foà R; Gaidano G
Blood; 2012 Mar; 119(12):2854-62. PubMed ID: 22308293
[TBL] [Abstract][Full Text] [Related]
16. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
Shindiapina P; Brown JR; Danilov AV
Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
[TBL] [Abstract][Full Text] [Related]
17. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
18. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
19. Richter transformation in the era of novel agents.
Ding W
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):256-263. PubMed ID: 30504319
[TBL] [Abstract][Full Text] [Related]
20. Targeting p53 in chronic lymphocytic leukemia.
Moia R; Boggione P; Mahmoud AM; Kodipad AA; Adhinaveni R; Sagiraju S; Patriarca A; Gaidano G
Expert Opin Ther Targets; 2020 Dec; 24(12):1239-1250. PubMed ID: 33016796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
